Nalaganje...
Targeting cancer with antibody-drug conjugates: Promises and challenges
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...
Shranjeno v:
| izdano v: | MAbs |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8300931/ https://ncbi.nlm.nih.gov/pubmed/34291723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2021.1951427 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|